Abstract
Kidney failure affects more than 725,000 individuals in the United States (US) with an estimated 63% of patients receiving hemodialysis and 7% of patients receiving peritoneal dialysis in 2016.1 Patients with kidney failure receiving hemodialysis have an increased risk of bleeding, thrombosis, and cardiovascular events vs. patients without kidney failure.2 Despite clear thrombotic risk in patients with kidney failure, especially those with atrial fibrillation,1 anticoagulant and antiplatelet use is tempered by limited evidence of efficacy, lack of randomized clinical trials, and concern for serious bleeding in patients with atrial fibrillation undergoing long-term dialysis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
